Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease | NEJM Skip to main content
NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …

Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative
colitis (UC), has emerged as a global disease with high incidence, long duration …

Neutralizing tumour necrosis factor (TNF) antibodies have been widely used to treat
inflammatory bowel disease (IBD) in the clinical practice. In this review, the principal …

Gut microbial dysbiosis and altered metabonomics have been implicated in the
pathogenesis of Crohn's disease (CD). The aim of our study was to characterize the gut …

Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD)
characterized by intestinal inflammation. Increased intestinal levels of the proinflammatory …

The knowledge on how gut microbes contribute to the inflammatory bowel disease (IBD) at
the onset of disease is still scarce. We compared gut microbiota in newly diagnosed …

Background Inflammatory bowel disease (IBD) is a chronic relapsing-remitting disease. An
adverse immune reaction toward the intestinal microbiota is involved in the pathophysiology …

Abstract Background and Aims Inflammatory bowel diseases [IBDs], Crohn's disease [CD]
and ulcerative colitis [UC], are globally increasing chronic gastro-intestinal inflammatory …

Current inflammatory bowel disease (IBD) treatments including non-biological, biological,
and nutritional therapies aim to achieve remission and mucosal healing. Treatment efficacy …

Inflammatory bowel disease (IBD), a chronic gut immune dysregulation and dysbiosis
condition is rapidly increasing in global incidence. Regardless, there is a lack of ideal …